Fulgent Genetics 3Q2026 conference call and webcast - FULGENT GENETICS INC

Financial Performance:

• Total Q3 2026 revenue was $90.4 million, an 8% year-over-year and 6% sequential increase, driven by the integration of BACO Diagnostics and StrataDx.
• GAAP gross margin was 35.3%, while Non-GAAP gross margin improved to 36.3% sequentially due to better collection rates and fixed cost leverage.
• GAAP net loss narrowed to $13.2 million ($0.48 per share) from $29.5 million ($1.06 per share) in Q2, primarily due to a $2.2 billion one-time impairment charge in Q2 and $3.2 million in bad debt recovery.
• Non-GAAP net loss was $2.4 million ($0.09 per share), compared to a deeper loss in the prior quarter; Adjusted EBITDA loss improved to $7.5 million from $17.1 million.
• GAAP operating expenses decreased to $54.5 million from $61.8 million, reflecting the absence of the Q2 impairment charge and bad debt recovery.
• Cash and equivalents increased to $652.4 million, supported by a $112.3 million federal tax refund, with a projected year-end cash position of approximately $630 million.
• Stock repurchases included over 15,000 shares in Q3, with 7.5 million total shares repurchased since inception and 75.6 million remaining.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance remains $330–$340 million (2.3%–5.4% YoY growth), comprising Precision Diagnostics ($161–$165M), Anatomic Pathology ($146–$150M), and Biopharma Services ($23–$25M).
• Full-year Non-GAAP gross margins are expected in the mid-30% range; Non-GAAP operating margins are projected in the low negative 20% range (improved from mid-negative 20%).
• Full-year Non-GAAP loss per share guidance improved to $1.65–$1.75 (from $2.22–$2.35), reflecting disciplined spending and lower operating expenses.
• Therapeutic development investment for 2026 is projected at approximately $21 million, down from previous estimates.
• Management anticipates Q4 revenue to potentially exceed the sequential midpoint of the guidance range, aiming for the upper end of the $330–$340 million total year range.

Business Segments and Product Lines:

• Precision Diagnostics revenue was $41.8 million (down 18% YoY, up 1% sequentially); Anatomic Pathology revenue was $40.9 million (up 57% YoY, up 9% sequentially); Biopharma Services was $7.7 million (up 5% YoY, up 19% sequentially).
• Therapeutics: FID-007 (nano-encapsulated paclitaxel) has completed the majority of Phase II; an end-of-Phase II FDA meeting occurred in August, with Phase III preparation underway for head and neck cancer.
• Therapeutics: FID-022 (nano-encapsulated SN38) for solid tumors is in Phase I dosing escalation; maximum tolerated dose expected in H1 2027.
• Both FID-007 and FID-022 utilize Fulgent's proprietary "clean chemo" nano-drug delivery platform, owned entirely by the company.
• Laboratory AI: AI platform analyzed 255,000 slide images (up 23% QoQ); failed analysis rate dropped to 0.01%; four modules in production with a prostate cancer module undergoing evaluation.
• AI Infrastructure: Transitioned to a new analysis platform improving speed, reliability, and scalability; five additional AI applications planned for Q4 2026 deployment.
• Integration: BACO and StrataDx integration efforts continued, contributing to overall performance and expanded sales cross-selling opportunities.

Market and Competitive Landscape:

• PAMA (Payment for Affordable and Modernized Access) impact is expected to be minimal as primary CPT codes have limited exposure to contemplated fee schedule reductions.
• AI utilization and digital pathology solutions are scaling rapidly, with technical reliability improving substantially as volume increases.
• Management notes increased seasonality shielding due to business diversification across pathology, rare disease, women's health, and biopharma services.
• Continued focus on strategic partnerships for therapeutic commercialization to leverage resources and strategy alignment.

Risks and Challenges:

• Billing and Revenue Cycle Management (RCM) transition continues to delay billing and impact third-quarter results, though collection rates are showing sequential improvement.
• Exact timing for returning to historical collection rates remains uncertain due to remaining system customizations.
• Clinical trial risks and uncertainties associated with bringing FID-007 and FID-022 to market.
• Potential future changes in the reimbursement landscape and clinical lab fee schedules, though currently viewed as manageable.
• Market competition and the need to maintain efficacy/toxicity profiles against conventional chemotherapy.

Management Commentary and Tone:

• Tone was optimistic regarding clinical pipeline momentum and operational improvements, particularly in the RCM transition and AI integration.
• Management expressed confidence in the "clean chemo" platform strategy and its potential to drive large-scale commercialization.
• Leadership acknowledged the challenges of the billing transition but emphasized "clear line of sight" to recovery and sequential progress.
• CFO Paul Kim and CEO Ming Hsieh highlighted disciplined cost management and improved cash flow as key drivers for the updated guidance.

Analyst Questions and Answers:

• RCM Transition Status: Management indicated the transition is "deep into the game" with significant customizations complete; gross margin improvement arrived faster than expected, with further upside anticipated as fine-tuning continues.
• Q4 Revenue Dynamics: Management clarified that while the midpoint of guidance implies flat Q4 growth, they are targeting a sequential increase and have reserved the right to exceed the $340M upper bound.
• AI ROI: AI implementation is driving efficiency, quality assurance (reducing errors), and pathologist productivity, with anticipated future margin improvements.
• BACO Integration: Ongoing progress in aligning sales organizations and cross-selling the expanded testing menu; no specific P&L KPI quantification provided yet beyond general efficiency gains.

Other Key Points:

• The company received a delayed $112.3 million federal tax refund, significantly boosting the year-end cash forecast.
• Non-GAAP financial measures exclude equity-based compensation, intangible asset amortization, impairment charges, and acquisition-related costs.
• Fulgent did not provide forward-looking reconciliations for Non-GAAP measures due to the unpredictability of equity-based compensation and other one-time items.
• The company plans to report 2027 guidance when releasing next quarter's results.